Trial · NCT05823012
Results by group188
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 188
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose Conversion Factor | XP-8121 | 4.24 | 90% Confidence Interval 4.06 to 4.42 | Ratio | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 1 Dosing / 0 - None | 43 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 1 Dosing / 1 - Very Slight | 3 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 1 Dosing / 2 - Slight | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 1 Dosing / 3 - Moderate | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 1 Dosing / 4 - Severe | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 2 Dosing / 0 - None | 41 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 2 Dosing / 1 - Very Slight | 2 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 2 Dosing / 2 - Slight | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 2 Dosing / 3 - Moderate | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 2 Dosing / 4 - Severe | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 3 Dosing / 0 - None | 41 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 3 Dosing / 1 - Very Slight | 2 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 3 Dosing / 2 - Slight | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 3 Dosing / 3 - Moderate | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 3 Dosing / 4 - Severe | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 4 Dosing / 0 - None | 37 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 4 Dosing / 1 - Very Slight | 5 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 4 Dosing / 2 - Slight | 0 | Participants | |
| Tolerability Assessment: Modified Draize Scale - Erythema | XP-8121 | Titration Period: Week 4 Dosing / 3 - Moderate | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05823012/results